none
Conditions
Interventions
N Group:Patients received standard reversal dose of intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg
HN+HS Group:Patients received 1 mg/kg of intravenous sugammadex three minutes after a standard neostigmine reversal dose.
HN+LS Group:Patients received 0.5 mg/kg of intravenous sugammadex three minutes after a standard neostigmine reversal dose
S Group:Patients received 2 mg/kg of intravenous sugammadex
Sponsors
The First Affiliated Hospital of Wenzhou Medical College, Zhejiang, China.
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients were eligible for entry into the trial if they were at least 18 yr but <65 yr of age, ASA physical status I-III, and were scheduled for elective surgery requiring muscle relaxation, in a supine position under sevoflurane anesthesia, with an anticipated duration of about 1-2.0 h. Only patients who had given written informed consent were included.
Exclusion criteria
Exclusion criteria: Patients who have not agreed to enroll in the study protocol; history of known or suspected neuromuscular disease; history of renal or hepatic dysfunction; hyperkalemia; patients receiving antibiotics, anticonvulsants, or magnesium; history of stroke; glaucoma; breastfeeding; pregnancy;suspected history of malignant hyperthermia or an allergy to medications used during general anesthesia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The time from the start of administration of sugammadex or neostigmine to recovery of the T4/T1 ratio to 0.9; | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of times oxygen saturation drops below 92 within 1h after extubation;Postoperative complications and management measures; | — |
Countries
China
Contacts
Public ContactZhu Weijuan, Chen Hongfei
The First Affiliated Hospital of Wenzhou Medical College, Zhejiang, China.
Outcome results
None listed